

TO: RNS
FROM: CT Global Managed Portfolio Trust PLC
DATE: 2 December 2025
SUBJECT: Issue of Equity
LEI: 213800ZA6TW45NM9YY31

The Board of CT Global Managed Portfolio Trust PLC ("the Company") announces that on 2 December 2025 the Company sold 100,000 Growth shares of £0.046131176 each from treasury at a price of 301.75p per Growth share and allotted 250,000 Income shares of £0.046131176 each, from the Company's general business purposes blocklisting facility at a price of 124.75p per Income share. These Income shares will rank *pari passu* with the existing Income shares in issue and dealings are expected to commence on 4 December 2025.

Following this issue, the Company has the ability to issue 184,510 Income shares and 1,304,550 Growth shares under its blocklisting facilities.

Following this transaction the Company's issued share capital consists of 56,432,194 Income shares and 38,756,710 Growth shares, of which nil Income shares and 5,388,000 Growth shares are held in treasury. Therefore the total number of shares with voting rights in CT Global Managed Portfolio Trust PLC is 56,432,194 Income shares and 33,368,710 Growth shares.

The above figures (56,432,194 Income shares and 33,368,710 Growth shares) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CT Global Managed Portfolio Trust PLC under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:

Adam Norris, Columbia Threadneedle Investment Business Limited 0131 573 8360
Paul Green, Columbia Threadneedle Investment Business Limited 0131 573 8360
Ian Ridge, Columbia Threadneedle Investment Business Limited 0131 573 8316

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seq.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEQLLFBELLXFBB